tbuckley/cabot-search huggingface dataset:
Correlation of tumor integrins and peritoneal carcinosis capability of gastric cancer.
Authors: M. Scartozzi, C. Loretelli, I. Bearzi, A. Mandolesi, E. Galizia, M. Pistelli, A. Bittoni, R. Berardi, F. Giorgi, S. Cascinu
Journal: Journal of Clinical Oncology (2010)

e14539 Background: The availability of multiple treatment options for peritoneal carcinosis from gastric cancer has re-opened the question of patients selection. Unfortunately to date no factors proved able to predict peritoneal-only recurrence. Preclinical studies suggested that integrins may play a critical role in the process leading to gastric cancer diffusion. Our study investigated the role of tumor integrins polymorphisms in determining either peritoneal carcinosis or hematogenous metastases in radically resected gastric cancer. Methods: Tumor integrins genotyping was performed on pT3 radically-resected gastric tumors with peritoneal-only carcinosis or hematogenous metastases. Results: The following factors resulted independently associated with peritoneal carcinosis or hematogenous metastases: the G allele of rs2269772 (ITGA3) (peritoneal carcinosis vs. hematogenous metastases: 48% and 84% respectively, p= 0.0003), the A allele of rs2269772 (ITGA3) (peritoneal carcinosis vs. hematogenous metastases: 16% and 0% respectively, p= 0.007), the C allele of rs11902171 (ITGV) (peritoneal carcinosis vs. hematogenous metastases: 20% and 4% respectively, p= 0.002), the G allele of rs11902171 (ITGV) (peritoneal carcinosis vs. hematogenous metastases: 41% and 64% respectively, p= 0.04), diffuse histology (peritoneal carcinosis vs. hematogenous metastases: 57% and 22% of patients respectively, p= 0.0008) and intestinal histology (peritoneal carcinosis vs. hematogenous metastases: 36% and 71% respectively, p= 0.001). Conclusions: Genotyping of rs2269772 (ITGA3) and rs11902171 (ITGV) may represent a critical asset in the definition of high risk patients for peritoneal carcinosis. The selection tool deriving from this analysis may allow an optimal use of innovative treatment strategies in gastric cancer patients. OR for tumor integrins polymorphisms at multivariate analysis. OR for peritoneal carcinosis p 95% CI rs2269772 (ITGA3, A) 22.2 0.03 1.2-40 rs11902171 (ITGV, C) 6.8 0.01 1.3-33.4 Diffuse histology 4.7 0.0005 1.9-11.3 OR for hematogenous metastases p 95% CI rs2269772 (ITGA3, G) 5.5 0.0003 2.2-14.15 rs11902171 (ITGV, G) 2.5 0.02 1.1-5.7 Intestinal histology 4.2 0.0008 1.8-9.9 No significant financial relationships to disclose.
New and Appropriate Goals for Parkinson Disease Physical Therapy
Authors: J. Eric Ahlskog
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV.
Authors: Robert Morlock, Elaine Yu, Joshua Ray
Journal: Journal of Clinical Oncology (2013)

417 Background: Trial results from ML18147 and VELOUR have recently reported outcomes for BV+CT and AFLI+CT in mCRC patients previously treated with BEV. This study evaluates cost and outcomes of BV+CT vs AFLI+CT as 2L treatment for patients with mCRC who progressed after receiving a standard BEV containing regimen in the 1L setting. Methods: In the absence of head-to-head trials comparing BV+CT &amp; AFLI+CT, an adjusted indirect comparison was conducted using the Bucher-method. Hazard ratios (HRs) from ML18147 comparing BV+CT vs CT and patients previously treated with BV in VELOUR comparing AFLI+CT vs CT were utilized. An illness-death Markov model was enhanced looking at three states (progression free, progression and death). Distributions were fit to the risks for progression (Lognormal) and mortality (Gamma) and assessed using the adjusted indirect HRs. Only direct costs were considered for patients. Costs of drugs were based on wholesale acquisition costs and costs of treating adverse events were based on Medicare reimbursement. Utilities were derived from the literature; costs and outcomes were discounted at 5%. A probabilistic sensitivity analysis (PSA) was conducted to evaluate robustness of results. Results: Results of the analysis suggest BV+CT combination is less costly compared to AFLI+CT ($39,104 less per treated patient) and similar effectiveness between BV+CT and AFLI+CT [OS 13.3 vs. 12.5 months; HR 0.94 (95% CI 0.70-1.26); 0.498 vs. 0.479 QALYs] in 2L treatment of mCRC in patients previously treated with BV. AE rates and costs were higher for the AFLI+CT arm compared to the BV+CT arm. PSA shows that BV+CT is dominant over AFLI+CT in 98% of model iterations. Increasing the efficacy of AFLI+CT by approximately 100% resulted in an incremental cost-effectiveness ratio of more than $200,000 and AFLI+CT remained dominated by BV+CT. Conclusions: Based on current available data, analysis suggest BV+CT presents lower costs and similar effectiveness outcomes than AFLI+CT in 2L treatment of mCRC in patients previously treated with BV. The higher price of AFLI and the increased rates of AEs are the primary drivers of model results.
Mycobacterial characteristics of tuberculous lymphadenitis in a tertiary care hospital in India
Authors: Madhav Kale, Parag Khatavkar, Meenakshi Satpute, Nilima Telang, Sneha Wagh
Journal: European Respiratory Journal (2011)

Introduction: Tuberculous lymphadenitis (TBLN) shows geogrophical variations. In developing countries, Mycobacterium tuberculosis is common pathogen, while in developed countries nontuberculous mycobacteria are common pathogens. Bacteriological studies are necessary to confirm the diagnosis and for proper management.

Aims: To study: 1. Mycobacterial smear and culture positivty rate in histologically proven tuberculous lymph nodes. 2. Cultural characteristics of mycobacteria. 3. Prevalence of multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis.

Methods: Lymph node smear for acid-fast bacilli (AFB) was done by Ziehl-Neelsen method, and culture was done by radiometric method (MB/Bact 240 system). Sensitivity tests for antitubercular drugs were performed by conventional method on LJ medium.

Results: During Jan. 2005 to Sept. 2010, mycobacteria were grown on 74 cultures. 72 cultures (97.3%) were positive for Mycobacterium tuberculosis, and only 2 (2.7%) were positive for M. Kansasii . In 89 histopathologically proven patients of TBLN, 56 (62,9%) cultures were positive and AFB smear positive in 21 (23.6%) patients. In 18 culture positive patients, histopathology of lymph nodes was not available. MDR TB was present in 12 (16.2%) cultures. XDR TB was not detected.

Conclusions: 1. Mycobacterium tuberculosis is the common organism in TBLN. 2. In histopathologically proven patients with TBLN, mycobacterial smear and culture positivity rates were 23.6% and 62.9% respectively. 3. MDR TB was present in 16.2% of patients.

References: 

*   1. G. Natraj: Correlation of fine needle aspiration cytology, smear and culture in tuberculous lymphadenitis: a prospective study. J. Postgrad. Med. 2002:48(2):113-116.
Abstract 18337: Comparison of the Distribution and Predictive Value of Framingham Risk Factors and Coronary Artery Calcium for Major Coronary Events Between Asian (South Korean) and Framingham Cohorts
Authors: Eun Ju Chun, Oyere K Onuma, Karol Pencina, Joseph M Massaro, Christopher J O’Donnell, Udo Hoffmann
Journal: Circulation (2013)

Background: Coronary artery calcium (CAC) predicts major adverse cardiovascular events (MACE) beyond Framingham risk factors (RF) across multiple ethnic groups within the United States. However, its value in other, non-US populations is unknown. Methods: We prospectively obtained data on RF and MACE in asymptomatic adults from the registry-based ESCORT Study (4502 Koreans) and the population-based Framingham Heart Study (FHS, 3141 Whites), who underwent computed tomography to assess CAC. The primary composite endpoint of MACE included CV death, acute myocardial infarction and unstable angina with revascularization. We compared association of traditional RF and CAC with MACE in the two cohorts using multivariate Cox proportional hazard regression analysis, examining CAC both as a categorical variable using established cut-points and as a continuous variable using log 2 [CAC + 1]. We tested for interaction between ethnicity and CAC categories. Results: Over median 55 (ESCORT) or 60 (FHS) month follow-up, there were 95 MACE (ESCORT=45, FHS=50). ESCORT participants had greater prevalence of smoking, diabetes and hypertension (p&lt;0.001 all) and greater 10-year Framingham risk score (11.4% vs 8.2%). In contrast, mean CAC prevalence and score were significantly lower in ESCORT (21.9%, 25.3 Agatston units, AU) vs FHS (41.5%, 99.9 AU). In ESCORT, more RF (age, male sex, systolic BP, HDL_C, diabetes) were predictive of MACE vs FHS (age only.) After adjustment for standard RF, doubling of CAC score (1-unit increase in log 2 [CAC + 1]) resulted in a 40% increase in risk of MACE in each cohort. Low CAC (1-100) was a significant predictor of MACE only in ESCORT but not in FHS (interaction p-value = 0.099.) Conclusion: There were significant differences in the burden and distribution of RF and CAC between Asian (South Korean) and white US (FHS) cohorts . CAC is a strong predictor of MACE in both cohorts, however lower CAC scores have greater predictive value in the Korean cohort.
Modular composition and dynamics of native GABAB receptors identified by high-resolution proteomics
Authors: Jochen Schwenk, Enrique Pérez-Garci, Andy Schneider, Astrid Kollewe, Anne Gauthier-Kemper, Thorsten Fritzius, Adi Raveh, Margarita C Dinamarca, Alexander Hanuschkin, Wolfgang Bildl, Jürgen Klingauf, Martin Gassmann, Uwe Schulte, Bernhard Bettler, Bernd Fakler
Journal: Nature Neuroscience (2015)
Abstract P199: Mean Lipoprotein Levels and Composition in South Asian-Americans Compared to the US Population
Authors: Elena Flowers, Cesar Molina, Ashish Mathur, Bradley Aouizerat, Mintu Turakhia
Journal: Circulation (2012)

Background South Asians have increased disk for cardiovascular disease (CVD) that is not captured by traditional risk factors, including TC and LDL-c. Low-density apolipoprotein-B (apoB) containing lipoproteins are heterogeneous in size and composition, and the particles with the greatest triglyceride content are thought to ultimately be the most atherogenic. Specific composition of low-density lipoproteins is not captured by common lipid measures (i.e. TC, LDL-c). A high proportion of triglyceride-rich low-density lipoproteins could be a mechanism for CVD risk in South Asians. Our objective was to compare mean TC, LDL-c, HDL-c, triglycerides, and apoB-triglyceride ratio (an estimate of low-density lipoprotein content) between South Asian-Americans and the US population. Methods We studied 2,876 South Asian adults living in the United States participating in a wellness program. Demographics were obtained by self-report. Lipoprotein levels were measured after 10-hour fast. US population means were calculated from NHANES (2007-2008, n = 5,113). Individuals on lipid-lowering therapy were excluded (780 (33%) South Asians, 1,194 (19%) NHANES). Results LDL-c (118mg/dL vs 116mg/dL, p&lt;0.05) and triglycerides (139mg/dL vs 131 mg/dL, p&lt;0.05) were higher in South Asians than the US population, whereas TC was lower (192mg/dL vs 197 mg/dL, p&lt;0.05). HDL-c was lower in South Asians (46mg/dL vs 52mg/dL, p&lt;0.05). ApoB was not statistically significantly different (93mg/dL vs 92mg/dL, p = 0.1), however the apoB/triglyceride ratio was lower in South Asians (0.8 vs 0.9, p&lt;0.05). After stratifying for age by decade and gender, we found that South Asians have lower HDL-c until the age of 50, and lower apoB/triglyceride ratio until the age of 60, with no substantial differences between men and women. Conclusions Mean TC, LDL-c, and triglycerides were normal in South Asians, however the apoB/triglyceride ratio was lower in South Asians than in the US population. This finding indicates that a higher proportion of low-density lipoproteins in South Asians are of the triglyceride-rich atherogenic type. This may portend non-HDL-c as a better indicator of CVD risk than LDL-c in South Asians. Further, low apoB/triglyceride ratio and low HDL-c occurs at a young age in South Asians, suggesting that onset of risk is early. The disappearance of these patterns after age 60 may be the result of sample bias (excluding individuals on lipid lowering therapy), and/or survival bias.
A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles
Authors: D. Murphy, D. Crowther, J. Renninson, J. Prendiville, M. Ranson, M. Lind, U. Patel, M. Dougal, C.H. Buckley, V.R. Tindall
Journal: Annals of Oncology (1993)
Clinical and Immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi-institutional phase II clinical trial
Authors: M. Ross, L. H. Camacho, E. M. Hersh, C. K. Brown, J. Richards, P. Mitsky, E. Wasserman, S. Lee, N. Bercovici, D. Landais, A. Ribas
Journal: Journal of Clinical Oncology (2007)

3004 Background: We have previously reported that vaccination with IDM therapeutic vaccine (IDD-3/Uvidem [Uvidem is co-developed with SANOFI-AVENTIS]) composed of dendritic cells (DC) loaded with three allogeneic lysates from tumor cell lines can elicit immune and anti-tumor responses. We describe here the preliminary results from a phase II clinical trial in metastatic melanoma patients. Methods: DC-MEL-202 is a single arm, two-stage phase II trial designed to evaluate clinical and immunological activities and the safety of a multivalent DC vaccine in patients with in-transit or low volume metastatic melanoma. There was no HLA restriction. Autologous DC were generated, under GMP conditions, from monocytes cultured in GM-CSF and IL-13, loaded with three allogeneic melanoma tumor lysates (M44, SK-MEL 28 and COLO 829) and matured with a combination of bacterial extract (FMKP) and IFN-γ, generating up to 15 doses of the vaccine containing 25x10 6 DC. Patients received six bi-weekly and two 6-weekly injections (id and sc). Clinical responders were eligible to receive additional doses. Immune response against tumor-associated antigens (TAA) peptides was assessed, at several time points, by detection of IFN-γ producing cells by flow cytometry Results: 33 patients were treated. To date: Vaccination is well tolerated with toxicity limited to mild events (only one possibly related SAE, age-related macular degeneration, was reported). Clinical response (RECIST): 6 patients showed evidence of clinical benefit (1CR, 1PR and 4 SD) with duration of response ranging from 7.5 to 22 months. Assessment of pathological response in target sites in 2 pts (1 PR, 1 SD) showed no residual disease.. 23/33 patients are still alive with a mean follow-up of 11mo (range 3–22mo). Mature data of PFS and OS will be presented. Immune response: 21 (84 %) out of 25 evaluated patients showed detectable TAA-specific CD8 + T cells with ten showing boosted or appearance of anti-TAA specific CD8 + T cells. Conclusions: Vaccination with IDD-3/Uvidem is safe and can elicit tumor specific CD8 + T cells not limited to HLA-A2+ patients. Substantial clinical benefit warrants further development of IDD3. No significant financial relationships to disclose.
Estrogen Profiles in Young Women: Effect of Maternal History of Breast Cancer2
Authors: R. W. Morgan, D. V. Vakil, J. B. Brown, L. Elinson
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Estrogen Profiles in Young Women: Effect of Maternal History of Breast Cancer Get access R. W. Morgan, R. W. Morgan Search for other works by this author on: Oxford Academic PubMed Google Scholar D. V. Vakil, D. V. Vakil Search for other works by this author on: Oxford Academic PubMed Google Scholar J. B. Brown, J. B. Brown Search for other works by this author on: Oxford Academic PubMed Google Scholar L. Elinson L. Elinson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 5, May 1978, Pages 965–967, https://doi.org/10.1093/jnci/60.5.965 Published: 01 May 1978 Article history Received: 19 September 1977 Accepted: 11 November 1977 Published: 01 May 1978
Lung function at age 8 and 16 yrs in moderate-to-late preterm children
Authors: Per Thunqvist, Erica Schultz, Eva Berggren-Broström, Per M. Gustafsson, Mikael Norman, Magnus Wickman, Erik Melén, Jenny Hallberg
Journal: European Respiratory Journal (2013)

Background Lung function development in infancy and early childhood of infants born moderate-to-late preterm (32-36 gestational weeks) has been shown to be impaired compared to term children. Reports on long-term development of lung function are sparse, although catch-up growth from early school-age to adolescence has been suggested.

Aim We hypothesize that moderate-to-late preterm children will have reduced lung function at 8 and 16 years compared to those born at term.

Methods The prospective BAMSE birth cohort (n= 4089) has baseline information on risk factors, gestational age and data from follow-ups at 1, 2, 4, 8, 12 and 16 yrs. Lung function, including spirometry, was compared between moderate-to-late preterms (32-36 w) and children born at term (37-41 w) at 8 (n=2455) and 16 yrs (n=1873, follow-up still ongoing). Adjustments were made for sex, age and height.

Results In BAMSE, 102 (5.4%) children were included in the moderate-late preterm group. At 8 yrs of age, FEV1/FVC was significantly lower (-1.57 % units, p=0.006) for the preterm group compared to term children, and a similar tendency was seen for FEV1 (-32 mL, p=0.089). At 16, both FEV1/FVC (-2.49 % units, p<0.001) and FEV1 (-121 mL, p=0.008) were significantly lower in the preterm group. Lung growth, estimated as FEV1 increase from 8 to 16 yrs, was significantly lower for preterm compared to the term group (-122mL, p=0.006). Analysing moderate (32-34 w) and late (35-36 w) preterms separately did not change the results.

Conclusions Children born moderate-to-late preterm had significantly reduced lung function at age 8 and 16 yrs. Their lung function decreased between 8 and 16 yrs compared to term children, indicating impaired lung growth.
Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts
Authors: P. C. Thuss-Patience, A. Kretzschmar, Y. Dogan, F. Rothmann, I. Blau, I. Schwaner, B. Lebedinzew, M. Grothoff, B. Dörken, P. Reichardt
Journal: Journal of Clinical Oncology (2008)

4551 Background: In the current study the combination capecitabine (cap) and docetaxel (doc) (CapDoc) is evaluated in two sequential patient cohorts with two different doses to develop a convenient out-patient regimen with an optimal efficacy and toxicity profile. Methods: Prospective multicenter phase II trial. Eligibility: Metastatic or locally advanced gastro-esophageal junction (GEJ) or gastric adenocarcinoma, ECOG PS 0–2, no prior palliative chemotherapy. Chemotherapy: Cohort I (coI): Doc 75mg/m2 d1, cap 2,000mg/m2 d1–14, q3w. Cohort II (coII): Doc 60mg/m² d1 and cap 1,600mg/m², d1–14, q3w. Results: 91 pts included, CoI: 40 pts; coII: 51 pts. Age: coI: 32–79 yrs (median 62) coII: 35–77 yrs (median 62), M/F coI: 29/11, coII: 39/12, ECOG PS 0/1/2: coI: 7/27/6 pts, coII: 11/30/10 pts. GEJ/ gastric body or not specified: coI: 20/20 pts, coII: 20/31 pts. Cycles administered: coI: 257 (median 6), coII: 247 (median 4). Dose reductions doc/cap coI: in 50/57.5 % of pts, coII 12/16 % of pts. Approx. % of planned dose delivered (doc/cap): CoI: 94/91%, coII 98/93%. Toxicity: In % of pts: Grade 1/2/3/4: Nausea: coI: 53/10/3/- %, coII: 31/16/4/- %, vomiting: coI: 18/13/-/3 %, coII: 10/14/4/- %, diarrhea: coI: 23/20/13/- %, coII: 22/10/10/- %, asthenia: coI: 38/40/10/- %, coII: 45/31/2/- %, stomatitis: coI: 23/15/10/- %, coII: 24/6/-/- %, alopecia: coI: 25/53/-/- %, coII: 41/22/-/- %, leuko-neutropenia: coI: 8/13/23/33 %, coII: 8/16/12/18 %, non neutropenic fever: coI: 10/20/3/- %, coII: 8/20/6/- %, neutrop. fever: coI: -/-/10/3 %, coII: -/-/2/- %, nail changes: coI: 33/28/-/- %, coII: 20/6/-/- %, paresthesia: coI: 18/18/5/- %, coII: 10/6/2/- %, dizziness: coI: 15/8/5/- %, coII: 24/-/-/- %, hand-foot-syndrome: coI: 25/18/18/- %, coII: 16/20/8/- %. Conclusion: These data suggest that dose reductions of doc or cap may compromize efficacy and are not recommended for reasons other than toxicity. CapDoc 2000/75 mg/m² is a well manageable convenient out-patient combination with very promising efficacy. Response Confirmed objective response (RECIST) Cohort I (n=40 pts) Doc 75/ Cap 2000 Cohort II (n=51 pts) Doc 60/ Cap 1600 evaluable 38 pts 49 pts CR 2 pts 5.0 % - - PR 18 pts 45.0 % 12 pts 23.5 % NC 15 pts 37.5% 24 pts 47.1 % PD 3 pts 7.5% 13 pts 25.5 % ORR (CR+PR) 50.0 % 23.5 % p=0.014 (Fisher´s exact, twosided) med time to tumor progression 5.6 mth 95%CI 3.9–7.3 3.9 mth 95%CI 2.9–5.0 med survival 10.1 mth 95%CI 7.3–13.0 7.7 mth 95%CI 4.3–11.1 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Roche, sanofi-aventis Roche, sanofi-aventis Roche, sanofi-aventis